5th Neuroimmunology Drug Development

Memo

Returning for its 5th year, the Neuroimmunology Drug Development Summit is excited to bring you pioneering insights from a range of brand-new speakers across the hottest biopharma in neuroimmunology to showcase revolutionizing breakthroughs in neuroinflammatory targeting. In 2023, you will enhance your understanding of underlying glial biology and neuroinflammatory pathways, address how to improve the development and translatability of neuroinflammatory biomarkers, and decipher the most effective in vitro and in vivo models to recapitulate all hallmarks of neuroglia. Join 100+ neuroimmunology and neuroinflammation industry experts across numerous neurological indications to define the next steps for accelerating the translation of neuroimmunology therapeutics into the clinic. URLs:Tickets: https://go.evvnt.com/1474943-2?pid=5569 Brochure: https://go.evvnt.com/1474943-3?pid=5569  Date and Time: On Tue, 25 Apr 2023 08:30 - Thu, 27 Apr 2023 16:30 Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States Prices:Industry Pricing - Conference Only: USD 2999.00,Industry Pricing - Conference + 1 Workshop: USD 3648.00,Industry Pricing - Conference + 2 Workshops: USD 4297.00,Vendor Pricing - Conference Only: USD 3799.00,Vendor Pricing - Conference + 1 Workshop: USD 4548.00,Vendor Pricing - Conference + 2 Workshops: USD 5297.00 Speakers: Anindya Bhattacharya, Senior Director and Head Of Neuroimmunology and Neuroscience Therapeutic, Johnson and Johnson Services, Inc, Bastian Zinnhardt, Biomarker Experimental and Medicine Leader, Hoffmann La-Roche, Bryan Ferguson, Senior Associate Scientist - Neuroimmunology, Biogen, Christian Mirescu, Vice President and Head of Neuroimmunology, Vigil Neuroscience, Dario Tejera, Scientist, Janssen Global Services, LLC, David Hansen, Associate Professor, Brigham Young University, Dimitry Ofengeim, Head of Precision Neurology and Neuroinflammation Cluster, Sanofi Genzyme, Fabrizio Gasparini, Executive Director, Head Of Neurodegeneration and Neuroinflammation, Neuroscience Research, Novartis AG, Florian Wanke, Discovery Scientist Neuroimmunology and Neuroinflammation, Roche, Iosif Pediaditakis, Associate Director, Neuroscience, Alchemab Therapeutics Ltd, Jennifer Munoz Pareja, Associate Professor, Division of Pediatric Critical Care Medicine, University of Miami School of Medicine, Juan Pablo de Rivero Vaccari, Associate Professor of Neurological Surgery and The Miami Project to Cure Paralysis, Miami Project to Cure Paralysis, Karpagam Srinivasan, Associate Director and Staff Scientist, Alector Pharmaceuticals LLC, Kevin Dines, Senior Director - Scientific, Preclinical Sciences and Neuroscience, Bristol-Myers Squibb Co., Manuela Polydoro, Head of Translational Medicine, Muna Therapeutics, Marianthi Papakosta, Associate Director, Takeda Pharmaceutical Co. Ltd., Massimiliano Bianchi, President and Chief Executive Officer, Ulysses Neuroscience, Matija Zelic, Senior Scientist, Precision Neurology and Neuroinflammation Cluster, Sanofi, Rebecca Mathew, Principal Scientist - Research, Merck and Co, Sherman Jia, Group Medical Director, Biomarker Development, Genentech Inc, Silke Miller, Director, Neuroscience Biomarkers, Janssen, Sunil Goodwani, Institute Associate Scientist - Neuropharmacology, MD Anderson Cancer Center, Tarek Samad, Senior Vice President and Head of Research, Lundbeck, Tim Hammond, Lab Head and Principal Scientist - Rare and Precision Neurology Research Cluster, Sanofi, Xiaoyu Liu, Scientist, Biogen